|Tufts University and Tufts Medical Center’s Institutional Biosafety Committee will hold an Open Meeting on Wednesday, December 11, 2013 at 5:30pm. The meeting will be held at 150 Harrison Avenue, Behrakis Auditorium, Room 130 in Boston.
Scope of Review Responsibility
Tufts University and Tufts Medical Center’s Institutional Biosafety Committees (IBC) was established under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to provide local review and oversight. Tufts voluntarily added regulation of infectious agents, select agents, and biological toxins research to the jurisdiction of the committee. The two IBCs are responsible for ensuring that all recombinant DNA research done at or sponsored by Tufts University or Tufts Medical Center is conducted in compliance with the NIH Guidelines and with proper concern for the safety of research personnel, the environment, and the surrounding communities.
The Tufts University Institutional Biosafety Committe (IBC) is based in Boston and regulates this research for the following:
- Tufts University Health Sciences Campus
- Tufts University Medford/Somerville Campus
- Human Nutrition Research Center on Aging
- Tufts Medical Center
The Cummings School of Veterinary Medicine at Tufts University (TCSVM) IBC is based in Grafton and regulates this research for the following:
IBC Review Responsibilities
- Regional Biosafety Lab
- Review of recombinant and synthetic DNA research conducted at, or sponsored by, the Institution for compliance with the NIH Guidelines
- Independent assessment of the containment levels required by the NIH Guidelines
- Assessment of the facilities, procedures, practices, and training and expertise of the personnel involved in recombinant or synthetic nucleic acid/infectious agent research
- Ensure that all relevant aspects of the NIH Guidelines have been appropriately addressed by the Principal Investigator
- Ensure that no research participant is enrolled in a human gene transfer experiment until the Recombinant DNA Advisory Committee (RAC) review process has been completed, Institutional Review Board approval has been obtained, and all applicable regulatory authorizations have been obtained
- Ensure compliance with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines and the Center for Disease Control (CDC) guidelines
- Adopt Exposure Response Plans covering accidental spills and personnel contamination resulting from recombinant or synthetic nucleic acid/infectious agent research
- Report any significant problems with, or violations of, the NIH Guidelines and any significant research-related accidents or illnesses to the appropriate Institutional Official and NIH/OBA within 30 days, unless the Principal Investigator has already
filed a report
A brochure is provided by the Office of Biotechnology Activities (OBA) at the National Institutes of Health to all institutions that utilize recombinant or synthetic nucleic acid molecules in research. All investigators with active IBC registrations are expected to review the information. The IBC suggests that it be posted in your laboratory.